1. Home
  2. COMP vs TGTX Comparison

COMP vs TGTX Comparison

Compare COMP & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Compass Inc.

COMP

Compass Inc.

HOLD

Current Price

$10.02

Market Cap

7.5B

Sector

Technology

ML Signal

HOLD

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

HOLD

Current Price

$52.14

Market Cap

6.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
COMP
TGTX
Founded
2012
1993
Country
United States
United States
Employees
3200
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.5B
6.0B
IPO Year
2021
2008

Fundamental Metrics

Financial Performance
Metric
COMP
TGTX
Price
$10.02
$52.14
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
10
5
Target Price
$11.80
$49.80
AVG Volume (30 Days)
12.0M
2.0M
Earning Date
05-05-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
67.74
1746.67
EPS
0.03
0.12
Revenue
$6,961,600,000.00
$2,785,000.00
Revenue This Year
$90.43
$49.08
Revenue Next Year
$8.63
$26.69
P/E Ratio
$332.50
$436.08
Revenue Growth
23.67
N/A
52 Week Low
$5.98
$25.37
52 Week High
$13.96
$54.07

Technical Indicators

Market Signals
Indicator
COMP
TGTX
Relative Strength Index (RSI) 68.80 82.82
Support Level $9.25 $28.57
Resistance Level $11.05 N/A
Average True Range (ATR) 0.56 2.43
MACD 0.19 1.13
Stochastic Oscillator 96.45 95.17

Price Performance

Historical Comparison
COMP
TGTX

About COMP Compass Inc.

Compass Inc provides an end-to-end platform that empowers residential real estate agents to deliver exceptional service to seller and buyer clients. The platform includes an integrated suite of cloud-based software for customer relationship management, marketing, client service and other critical functionality, all custom-built for the real estate industry and enabling core brokerage services. Business operations are conducted in the United States and earn revenue domestically.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline, it has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. Its pipeline includes UBLITUXIMAB, SUB-Q UBLITUXIMAB, and AZER-CEL. Geographically, it generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from the international market.

Share on Social Networks: